Anti-BAFF/BLyS Magnetic Beads Immunoprecipitation (IP) Kit

Temporarily not available outside of China.
Price:
Size:
Number:

Anti-BAFF/BLyS Magnetic Beads-IP Kit Product Components

Components Storage
Anti-BAFF/BLyS Magnetic Beads1,3 2-8℃ for 12 months
NP40 Cell Lysis Buffer2 -20℃ for 12 months
5×TBST(pH7.4)  
1×TBST(pH7.4)  
ddH2O  
Alkaline Elution Buffer 2-8℃ for 12 months
Acidity Elution Buffer 2-8℃ for 12 months
Neutralization Buffer 2-8℃ for 12 months

【1】The IP KIT contains anti-BAFF/BLyS magnetic Beads (2 mg/mL) in phosphate buffered saline (PBS, pH 7.4) with sodium azide (0.1%).

【2】Using NP-40 cell lysate buffer in the kit is required,otherwise,the magnetic beads may be precipitated.

【3】Shipping: Magnetic Beads kits are shipped at ambient temperature in which magnetic beads are provided in liquid buffer.

Anti-BAFF/BLyS Magnetic Beads-IP Kit Product Description

The Anti-BAFF/BLyS magnetic Beads, conjugated with Anti-BAFF/BLyS antibody, are used for immuneprecipitation (IP) of BAFF/BLyS proteins which expressed in vitro expression systems. For IP, the beads are added to a sample containing BAFF/BLyS proteins to form a bead-protein complex. The complex is removed from the solution manually using a magnetic separator. The bound BAFF/BLyS proteins are dissociated from the magnetic beads using an elution buffer.

Anti-BAFF/BLyS Magnetic Beads-IP Kit Antibody Information

Antibody
Anti-BAFF/BLyS Antibody, Rabbit Polyclonal(10056-RP02)
Immunogen
Recombinant Human BAFF / TNFSF13B protein (Catalog#10056-HNAE)
Species Reactivity
Human BAFF / TNFSF13B
Source
Polyclonal Human Rabbit IgG
Preparation
Produced in rabbits immunized with purified, recombinant Human BAFF / TNFSF13B (rh BAFF / TNFSF13B; Catalog#10056-HNAE; Q9Y275-1; Ala134-Leu285). BAFF / TNFSF13B specific IgG was purified by Human BAFF / TNFSF13B affinity chromatography.
Applications
Immunoprecipitation (IP), Minimum Protein Purification

Anti-BAFF/BLyS Magnetic Beads Immunoprecipitation (IP) Kit: Synonyms

Anti-BAFFALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-BLYSALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-CD257ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-DTLALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-TALL-1ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-TALL1ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-THANKALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-TNFSF20ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-ZTNF4ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit

BAFF/BLyS Background Information

B lymphocyte stimulator (BLyS), also known as TNFSF13B, CD257 and BAFF, is a single-pass type II membrane protein, which belongs to the tumor necrosis factor family. BAFF is abundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. BAFF is a cytokine and serves as a ligand for receptors TNFRSF13B (TACI), TNFRSF17 (BCMA), and TNFRSF13C (BAFFR). These receptors are a prominent factor in B cell differentiation, homeostasis, and selection. BLyS levels affect survival signals and selective apoptosis of autoantibody-producing B cells. Thus, it acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells. Overexpression of BLyS in mice can lead to clinical and serological features of systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). BLyS is an attractive therapeutic target in human rheumatic diseases. The ability of BLyS to regulate both the size and repertoire of the peripheral B cell compartment raises the possibility that BLyS and antagonists thereof may form the basis of a therapeutic trichotomy. As an agonist, BLyS protein may enhance humoral immunity in congenital or acquired immunodeficiencies such as those resulting from viral infection or cancer therapy.
Full Name
tumor necrosis factor (ligand) superfamily, member 13b
References
  • Nardelli B, et al. (2002) B lymphocyte stimulator (BLyS): a therapeutic trichotomy for the treatment of B lymphocyte diseases. Leuk Lymphoma. 43(7): 1367-73.
  • Stohl W. (2006) Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases. Endocr Metab Immune Disord Drug Targets. 6(4): 51-8.
  • Cancro MP, et al. (2009) The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 119(5): 1066-73.
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait U.S.A.